Inogen
Beverly, Massachusetts, United States · Biotechnology, Health Care, Manufacturing
Inogen is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Key facts
- Headquarters
- Beverly, Massachusetts, United States
- Employees
- 823
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (INGN)
- Website
- www.inogen.com
- Company page
Recent activity at Inogen
- : SEC 8-K (1.01): On September 29, 2026, Inogen, Inc. entered into an Asset Purchase Agreement with Rotech Healthcare Inc., agreeing to sell substantially all of its assets related to its United States oxygen rental business. The estimated aggregate purchase price is approximately $24.8 million, to be payable in six installments, and is subject to post-closing reconciliation. This transaction includes the transfer of specified on-rent and on-hand inventory as well as related patient records, and is contingent upon customary closing conditions. This agreement signifies a strategic shift for Inogen, indicating a focal move away from its oxygen rental operations.
- : Inogen Appoints Andy Reding as Chief Operating Officer
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On April 6, 2026, the Board of Directors appointed Vafa Jamali as a Class I director, effective immediately, to serve until the Company’s 2027 annual meeting of stockholders. Additionally, Mr. Jamali has been appointed to the Audit Committee and Compliance Committee. The Board confirmed his independence according to Nasdaq's standards. Mr. Jamali's compensation includes $45,000 annually for Board service, plus additional fees for committee roles, and he will receive restricted stock units with a fair value of $180,000 as part of his compensation package. This strategic appointment is expected to enhance the Board's expertise and oversight capabilities in the company's governance and compliance.
- : Inogen Appoints Jason Richardson as Chief Financial Officer and Dominic Hulton as Chief Marketing Officer
- : SEC 8-K (5.02):
- : SEC 8-K (7.01):
- : SEC 8-K (2.02): On January 12, 2026, Inogen, Inc. reported preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. The preliminary figures disclose that revenue is subject to change pending the completion of the audited financial statements, highlighting the importance of these results as they provide key insights into the Company's financial performance for the previous fiscal year. This early disclosure may affect investor sentiment regarding the Company's growth trajectory and operational efficacy. Detailed figures were not provided in the summary, but the results are critical for stakeholders awaiting final, audited reports.
- : Inogen Inc has launched the Voxi 5, a stationary oxygen concentrator aimed at improving support for businesses in the medical field.
Leadership
- Andy Reding, Chief Operating Officer
- Liladhar Bagad, VP, Chief Data and Information Officer (CDIO)
- Dominic Hulton, Chief Marketing Officer
- Jason Richardson, Chief Financial Officer
- Michael Bourque, Executive Vice President
- Kevin Smith, President
- Naga Rameswamy, Chief Technology Officer
- Kevin P. Smith, General Counsel
Verified email and direct lines for Inogen’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Inogen in the news
- Inogen to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire (Apr 23, 2026)
- Inogen Portable Oxygen Concentrator(s) Review 2026 - The National Council on Aging (NCOA) (Sep 23, 2026)
- Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists - Yahoo Finance (Aug 11, 2026)
- Ambulation and Long-Term Oxygen Therapy - EMJ (Jun 20, 2024)
- Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech - Business Wire (Sep 30, 2026)
- Inogen Announces Second Quarter 2026 Financial Results - Business Wire (Aug 06, 2026)
- Inogen Announces the Appointment of Vafa Jamali to Board of Directors - Business Wire (Apr 06, 2026)
- Inogen Announces First Quarter 2026 Financial Results - Business Wire (May 07, 2026)
Companies similar to Inogen
- Haag-Streit · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Accurate Medical Therapeutics Ltd · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- InMode · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Strata Critical Medical · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Minnetronix Medical · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Inogen: questions and answers
What does Inogen do?
Inogen is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Where is Inogen headquartered?
Inogen is headquartered in Beverly, Massachusetts, United States.
How many employees does Inogen have?
Inogen has about 823 employees.
Who leads Inogen?
Michael Bourque is an Executive Vice President at Inogen.
What is the latest news on Inogen?
On Sep 28, 2026, SEC 8-K (1.01): On September 29, 2026, Inogen, Inc. entered into an Asset Purchase Agreement with Rotech Healthcare Inc., agreeing to sell substantially all of its assets related to its United States oxygen rental business. The estimated aggregate purchase price is approximately $24.8 million, to be
Is Inogen a public company?
Yes. Inogen is publicly traded under the ticker INGN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy